PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC Jul 1, 2013.
Published in final edited form as:
PMCID: PMC3672055
NIHMSID: NIHMS463896
Examining Autism Spectrum Disorders by Biomarkers: Example From the Oxytocin and Serotonin Systems
Elizabeth Hammock, PhD, Jeremy Veenstra-VanderWeele, MD, Zhongyu Yan, PhD, Travis M. Kerr, B.S., Marianna Morris, PhD, George Anderson, PhD, C. Sue Carter, PhD, Edwin H. Cook, MD, and Suma Jacob, MD, PhD
Drs. Hammock and Veenstra-VanderWeele, and Mr. Kerr are with the Vanderbilt Kennedy Center for Research on Human Development at Vanderbilt University, Nashville, TN. Drs. Yan and Morris are with Wright State University School of Medicine, Dayton, OH. Dr. Anderson is with the Yale University School of Medicine, New Haven, CT. Drs. Carter, Cook, and Jacob are with the University of Illinois at Chicago, Chicago, IL.
Correspondence to Suma Jacob, MD, PhD, 1747 W. Roosevelt Rd., IJR, MC 747, University of Illinois at Chicago, Chicago, IL 60608; sjacob/at/psych.uic.edu
Objective
Autism Spectrum Disorder (ASD) is a heritable but highly heterogeneous neuropsychiatric syndrome, which poses challenges for research relying solely on behavioral symptoms or diagnosis. Examining biomarkers may give us ways to identify individuals who demonstrate specific developmental trajectories and etiological factors related to ASD. Plasma oxytocin (OT) and whole blood serotonin (5-HT) levels are consistently altered in some individuals with ASD. Reciprocal relationships have been described between brain oxytocin and serotonin systems during development. We therefore investigated the relationship between these peripheral biomarkers as well as their relationships with age.
Method
In our first study, we analyzed correlations between these two biomarkers in 31 children and adolescents who were diagnosed with autism and were not on medications. In our second study, we explored whether whole blood 5-HT levels are altered in mice lacking the oxytocin receptor gene, Oxtr.
Results
In humans, OT and 5-HT were negatively correlated with each other (p<0.05) and this relationship was most prominent in children under 11 years old. Paralleling human findings, mice lacking Oxtr showed increased whole blood 5-HT levels (p=0.05), with this effect driven exclusively by mice younger than 4 months of age (p< 0.01).
Conclusions
Identifying relationships between identified ASD biomarkers may be a useful approach to connect otherwise disparate findings that span multiple systems in this heterogeneous disorder. Using neurochemical biomarkers to do parallel studies in animal and human populations within a developmental context is a plausible approach to probe the root causes of ASD and identify potential interventions.
Keywords: autism, biomarker, serotonin, oxytocin, development
The pattern of behavioral symptoms now described as Autism Spectrum Disorder (ASD) was first recognized by Leo Kanner in 1943 1. ASD symptoms have been broken down into various numbers of subcategories by clinical consensus 2 and by statistical analysis 36. Current consensus is coalescing around two symptom domains: social communication impairment and fixed interests / repetitive behavior, with some support from factor analyses 79. Beyond these diagnostic domains, comorbid developmental, cognitive, and behavioral symptoms are common and diverse in ASD, including intellectual disability 10, sensory dysfunction 1116, and hyperactivity 17,18. A number of comorbid neurological and medical conditions are also common in ASD, including epilepsy 19, sleep problems 20, and constipation 21,22. Overall, the heterogeneity of diagnostic and associated symptoms suggests that diverse susceptibility factors may lead to social dysfunction and repetitive behaviors as a common final outcome. Biomarkers could potentially be used to parse this heterogeneity, which may ultimately lead to individualized interventions.
An ideal biomarker should be highly reproducible, as well as straightforward and economical to measure. The latter criteria can be achieved over time as technology improves. While we might hope for a diagnostic biomarker, this goal has proven elusive in behaviorally defined disorders. Alternatively, a biomarker could represent an intermediate phenotype that arises more directly from a particular genetic or environmental susceptibility factor and mediates the risk of the disorder itself 23. A biomarker could also be an endophenotype, a heritable trait that arises from an underlying genetic factor and could be separately mapped in genetic studies 24,25. We must also be vigilant for the possibility that a biomarker might be a secondary result of ASD symptoms or treatment, thereby being less useful for the identification of susceptibility factors. A number of biomarkers have been identified in ASD, including brain growth patterns and metabolic or immune markers 2632. The present study focuses on the relationship between blood measures of serotonin and oxytocin, two peripheral biomarkers that correspond to systems that interact in the brain.
Hyperserotonemia, or elevated blood serotonin (5-hydroxytryptamine; 5-HT) levels are found in 25–35% of individuals with ASD 3338. Whole blood 5-HT is contained almost entirely in platelets that take up 5-HT via the serotonin transporter as they pass through the enteric circulation, where 5-HT is synthesized and released by enterochromaffin cells. Blood 5-HT levels are correlated among children with ASD and their family members 3336 and 5-HT levels were found to have a heritability of ~1.0 in a large inbred population study 39. Abnormalities in the brain serotonin system are also reported in ASD, including evidence of altered serotonin synthesis 37,40 and receptor binding 41,42, as well as one report of dystrophic serotonergic axons 43. Thus, the overall evidence implicates the 5-HT system in ASD, but attempts to link the robust and heritable whole blood 5-HT levels to clinical symptoms have been inconsistent, with isolated reports of association with stereotyped or self-injurious behavior 4447.
Blood oxytocin (OT) levels are also a focus of ASD research. Children with autism have lower average levels of blood OT level in comparison to typically developing children matched for age 48, with a specific correlation with being rated as “aloof” using Wing’s typology 49. In contrast, a study of adults with ASD suggests that OT levels are higher at baseline in adults 50. Interest in the oxytocin system in ASD is supported by its important role in mammalian social behaviors, including social recognition, parenting behavior, and attachment 51-57. Mice lacking the oxytocin receptor gene (Oxtr) show reduced social recognition, increased susceptibility to seizures, and poor reversal learning, a laboratory proxy of cognitive flexibility 58,59. Genetic studies suggest a modest association of oxytocin receptor gene (OXTR) alleles with ASD6068, but see also 69,70. In addition to primary signaling molecules, allelic variation in CD38, a positive regulator of OT release 71,72, also shows association with ASD 73,74. Based upon the biomarker and genetic data, as well as the effects of OT on affiliative behavior across species, considerable interest is focused on the potential use of OT in ASD. Initial studies with intravenous or intranasal OT are promising 7579; although sufficient data are not yet available to judge whether it leads to sustained benefit or is safe for long-term use in adults or in children.
The serotonin and oxytocin systems interact in the brain, both during development and in adulthood. In rats and voles, early exposure to a non-selective serotonin receptor agonist results in fewer oxytocin (OT) cells in the paraventricular nucleus of the hypothalamus (PVN), less affiliative behavior, and less social interaction 80,81. Conversely, early exposure of vole pups to exogenous OT results in higher serotonin axon length densities in several brain regions 82. In humans, the 5-HT system regulates OT release in adults, as evidenced by increased OT levels following treatment with 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”), a drug that causes release of 5-HT 8388. Further, OT acts as an anxiolytic in adult mice via oxytocin receptors expressed in serotonin neurons 89.
The separate lines of evidence for blood 5-HT and oxytocin measures as biomarkers in ASD, coupled with the evidence for intersection between the corresponding systems in the brain, led us to examine the relationship between peripheral 5-HT and OT biomarkers in children and adolescents with ASD. We complemented this observational biomarker study with an experimental paradigm in mice lacking the oxytocin receptor gene, assessing whether genetic manipulation of the oxytocin system can impact the peripheral biomarker of whole blood 5-HT.
Human Participants
All participants were enrolled at the University of Illinois at Chicago Autism Center of Excellence and were recruited under a protocol studying rigid-compulsive features in ASD. They were assessed with ADI-R 90, the Autism Diagnostic Observation Schedule, ADOS 91 and clinical evaluation. Participants were included in this study if they were classified as strictly defined autism rather than autism spectrum disorder, because they met the classification criteria across diagnostic research instruments. Participants were screened to have no psychiatric medications and no medication use during the time the neurochemistry assays were completed for both plasma OT-RIA and whole blood 5-HT assays. In total, 31 unrelated probands were studied (mean age 8.8 ± 4.4 years; 28 male, 3 female; 27 reported to be of European ancestry).
Human Neurochemistry Biomarker Assays
OT concentrations in plasma were determined by a non-equilibrium plasma OT radioimmunoassay, as previously described 92. Briefly, plasma samples (~1.0 ml) were extracted using the acetone/petroleum ether method, lyophilized and stored at −80 °C until analysis. 125Iodine-labeled OT was purchased from PerkinElmer. OT was measured with antiserum (supplied by MM) 92. Bound hormone was separated from unbound with a secondary antibody (goat anti-rabbit IgG) and anti-rabbit gamma globulin (ARGG).
Whole blood 5-HT (WB5-HT) is a reliable measure of platelet 5-HT because greater than 99% of whole blood 5-HT is in the platelet fraction 93. Measurement of platelet 5-HT in platelet-rich plasma prepared by centrifugation can add variance due to 5-HT release during processing and variable platelet yield. Whole blood 5-HT was measured by HPLC with fluorometric detection, as described previously 94. Intra-assay and interassay coefficients of variation were 1.7 and 6.2%, respectively.
Animals
Oxtr mice (Oxtrtm1.1Knis) were a generous gift of Prof. Larry Young of Emory University. The mice were received on a mixed 129/C57 background 59 and fully backcrossed to C57BL/6J with confirmed backcrossing by strain-specific marker genotyping (Speed Congenics, The Jackson Laboratory, Bar Harbor, ME). Mice were maintained on corncob bedding on a 12:12 L/D cycle with ad libitum access to standard chow and water. All experiments were conducted with approval and oversight of the Vanderbilt University Institutional Animal Care and Use Committee following local, state and federal guidelines. Heterozygous breeder pairs were used to generate mixed litters containing wild type, heterozygous, and knockout animals. Co-housed littermate wild type and knockout males were used for experiments. Animals were weaned at the beginning of the fourth post-natal week and housed with same-sex littermates. PCR-based genotyping was performed on tail-samples with the following primers: Oxtr_common_For 5′-CTGGGGCTGAGTCTTGGAAG; Oxtr_WT_Rev 5′-CTCGATACTCCAGTTGGCTGC; Oxtr_KO_Rev 5′-GTTGGGAACAGCGGTGATTA.
Mouse whole blood 5-HT measurement
At harvest, 9 littermate pairs of animals (N = 18 mice) were scruffed, rapidly decapitated, and trunk blood was collected into a 1.5 mL microfuge tube containing 25 uL ACD Solution A (trisodium citrate, 22.0g / L; citric acid, 8.0 g / L; dextrose 24.5 g / L; Becton, Dickinson and Co., Franklin Lakes, NJ), mixed gently, immediately frozen on dry ice and stored at −80C until the time of analysis. 5-HT levels were measured in the Neurochemistry Core of Vanderbilt University by previously described HPLC electrochemical detection methods 95. Briefly, 5-HT levels were determined by a specific HPLC assay using an Antec Decade (oxidation: 0.7) electrochemical detector. 5-HT was eluted with a mobile phase consisting of 89.5% 0.1M TCA, 10−2 M sodium acetate, 10−4 M EDTA and 10.5 % methanol (pH 3.8). Concentration was determined by comparison with injections of known standards.
Statistical analyses
Statistical analyses for the human data set were conducted using PSAW Statistic v. 18 (SPSS Inc, Chicago, IL). Shapiro-Wilk and Kolmogorov-Smirnov normality tests were used to examine deviations from a normal distribution. OT was converted to fg/ml and log-transformed in subsequent tests for normalization prior to using parametric statistics. T-test or Pearson’s correlation was used to examine WB5-HT and log(OT) with respect to sex, ancestral background (European descent or other), and age in months. Pearson’s correlation was used to examine the relationship between WB5-HT and log(OT) with age as a covariate. Exploratory unpaired t-test was used to compare the ratio of WB5-HT / log(OT) in participants less than 11 years old or greater than 11 years old.
Statistical analyses for the mouse data set were conducted using GraphPad Prism v. 5 (LaJolla, CA). An omnibus normality test was used to examine deviations from a normal distribution. Pearson’s correlation was used to examine whether the dependent variable of mouse WB5-HT varied by age. Mouse WB5-HT levels were compared across genotype within littermate pairs using a paired t-test.
We initially examined if human OT plasma levels and WB5-HT were normally distributed and whether they differed by sex, reported ancestral background, and age (Table S1, available online). Although WB5-HT approached a normal distribution, OT was positively skewed (skewness = 2.7, kurtosis = 10.3) and required log transformation in all further analyses.
There were no significant differences in log(OT) and WB5-HT across sex (all p values >0.30) or reported ancestral background (all p values >0.44). Although log(OT) levels were not significantly correlated with age (r=0.14, N= 31, p = 0.22), WB5-HT was negatively correlated with age (r =−0.32, N= 31, p = 0.04) and was lower in adolescence than childhood (see Figure 1).
Figure 1
Figure 1
Whole blood serotonin (WB5-HT) levels in individuals with autism spectrum disorder (ASD) change across development. Note: (A) The level of WB5-HT negatively correlates with age in individuals with ASD (N=31). Males are shown with closed circles and females (more ...)
Log(OT) levels were significantly negatively correlated with WB5-HT (r=−0.37, N= 31, p = 0.04, Figure 2a) when controlling for age as a covariate with a partial correlation analysis. Exploratory analyses demonstrated that the ratio of WB5-HT to log(OT) was significantly different (t=3.0, p=.008, Figure 2b) in children under 11 years (M=91.2, SD=32.1) versus older children and young adults (M=61.7, SD=19.1) and similar to the pattern of differences in WB5-HT (t=2.4, p=.04, Figure 1b).
Figure 2
Figure 2
A relationship exists between plasma levels of oxytocin (OT) and whole blood levels of serotonin (WB5-HT) in individuals with autism spectrum disorder (ASD). Note: (A) The level of WB5-HT across log-transformed oxytocin (log(OT)) levels in individuals (more ...)
Paralleling the human sample, mouse WB5-HT levels did not deviate significantly from a normal distribution. In mice, WB5-HT levels showed a non-significant trend for a negative correlation with age (r=−0.40, N = 18, p < 0.10) when both genotypes were analyzed together (Figure 3A). In male Oxtr−/− mice, we observed higher concentrations of whole blood 5-HT compared to wild-type littermates (Figure 3B), (Paired student’s t = 2.29, N = 18, p = 0.05). Interestingly, a post-hoc analysis showed that this difference was evident in younger animals (male littermates < 4 months of age: paired student’s t= 8.82, N = 8, p < 0.01), but not in animals older than 4 months (male littermates > 4 months of age: paired student’s t = 0.43, N = 10, p = 0.69; (see Figures 3C–3D).
Figure 3
Figure 3
Congenital loss of the oxytocin receptor gene (Oxtr) is associated with higher serotonin levels (WB5-HT). Note: (A) There is a non-significant trend for a correlation (r=−.40, N=18, p<0.10) between WB5-HT and age across all mice, including (more ...)
Both the human and mouse data are consistent with a relationship between peripheral OT and 5-HT biomarkers. In humans, we observed a negative correlation between whole blood serotonin levels and peripheral OT levels. In mice, we observed that mice lacking the Oxtr gene had lower concentrations of whole blood serotonin. In both humans and in mice, the relationships were strongest in younger individuals.
The negative correlation between OT and 5-HT levels in the human data can be interpreted in a number of ways, as this relationship could be mediated at multiple levels. Platelet-poor plasma ultrafiltrate serotonin levels are not elevated in subjects with autism9698, suggesting that peripheral OT could affect either increased gastrointestinal synthesis, increased platelet serotonin uptake, or decreased serotonergic release from platelets 99. Conversely, peripheral 5-HT is unlikely to affect central OT release because it doesn’t cross the blood-brain barrier, but it could plausibly affect peripheral metabolism of OT. Importantly, a direct relationship is not required to explain the correlation, since both biomarkers could also be regulated in opposite directions by a shared pathway.
The decrease in whole blood 5-HT across development is consistent with previous reports in human samples 100. Although hyperserotonemia is not limited to prepubertal children100, previous work has shown a decrease or stabilization around the age of 12 years 101. This led to our selection of >11 years as a division point when considering the relationship between OT and WB5-HT. It is possible that the smaller dynamic range of WB5-HT in adolescents prevents this small sample from demonstrating a strong relationship with OT. If we compare our results with this cut-off to pre-pubertal healthy control children of European origin determined in the same laboratory using the same HPLC methodology, we observed a marked elevation in whole blood 5-HT. Reported WB5-HT reference ranges (mean+/−SD) for prepubertal white healthy control children were 190+/−44 (N=35) (Pfeffer et al., 1998), and 187+/−50 ng/ml (N=21) (McBride et al., 1998), in comparison to 278.8+/−84.9 ng/ml (N=22) in our population of children with ASD of European origin ≤ 11 years old. It is possible that our recruitment for a study examining rigid-compulsive symptoms in ASD, resulted in more young children with hyperserotonemia, but it is not possible to make a true assessment without a direct ethnic and age-matched control group.
The mouse data show that experimental alteration of the oxytocin system can affect platelet 5-HT levels. This suggests that the OT system is likely to directly or indirectly regulate the peripheral 5-HT system at some level, but it does not rule out a bidirectional relationship or explain the mechanism of regulation. The influence of oxytocin receptor (OXTR) absence could be at the level of the intestinal lumen102, where OXTR is expressed in the epithelium; although its co-expression in serotonin positive enterochromaffin cells is unknown. OXTR is unlikely to have a direct effect at the level of the platelet, where it does not appear to be expressed. The effects of OXTR could also be mediated through some intermediate system that in turn regulates the 5-HT system. Further, OXTR absence could affect the development of the peripheral 5-HT system or could have an ongoing effect in older animals. The stronger findings in the younger animals suggest that the relationship between these two systems in the periphery may, like the human correlation, be stronger earlier in development, thus highlighting the importance of patient age in the identification of biomarker interrelationships and subsequent reproducibility.
There are a number of limitations of these results. Both the human and the mouse sample sizes were small. This is particularly challenging with regard to sample sizes across development. The human sample was limited to children with ASD, so it is not possible to know whether the relationship between OT and 5-HT is specific to ASD or generally true regardless of diagnosis. With regard to the mouse data, elimination of the oxytocin receptor is a dramatic genetic change that should be expected to be extremely rare in humans, so it cannot be extended directly to the human data. Smaller perturbations in the oxytocin system may or may not parallel the effects seen with Oxtr deletion. Importantly, the human results appear to point to a change in the relationship between 5-HT and OT around the time of puberty, but Tanner staging data was not complete in this sample. In contrast, the mouse data are confined to post-pubertal animals beginning in adolescence and extending into adulthood. The parallels between human and mouse developmental processes are not clear with respect to the relationship between OT and 5-HT.
Future research should examine whether the relationship between blood OT and 5-HT levels is specific to children with ASD or extends into the general population. This work should also examine whether this relationship is particularly true for those individuals with hyperserotonemia relative to a control population or whether it corresponds to a quantitative relationship across the full range of 5-HT levels. The developmental course of OT and 5-HT levels within individuals also demands further study, both individually as well as in interaction with each other. In particular, Tanner staging or sex hormone status should be assessed in future work to examine whether 5-HT levels decline gradually over time or show a specific decrement at puberty. A larger sample size will be necessary to fully examine the impact of development, as well as other factors such as sex or ancestral background. Future work in the 5-HT system should also include considering whether peripheral levels correlate with brain measures (e.g. transporter binding, receptor binding, synthesis capacity). Further, it remains to be determined if these biomarkers relate to response to medications targeting the serotonin system, such as serotonin reuptake inhibitors. Pharmacological approaches could also be used to examine 1) how serotonergic drugs in humans as well as animals modulate OT levels and function and 2) how OT drugs (intranasal as well as peripartum pitocin) influence serotonin levels both in the brain and in the periphery. Mouse studies offer the possibility of more targeted experimental intervention, including selective deletion of Oxtr from specific cell types at particular points in development. Finally, studies of susceptibility factors could focus on individuals with low OT and high 5-HT levels that may allow mapping of genes or environmental factors that impact both systems.
As quantitative measures reflecting multiple genetic or environmental effects within a single system, biomarker assessment is an appealing way to study individuals with ASD. Despite this appeal, it is important to note that previous work has not connected hyperserotonemia to specific clinical features of the disorder. Future ASD biomarker research, whether focusing on peripheral neurochemistry or targeted neuroimaging, should integrate measures of multiple biomarkers in the same set of individuals, rather than continue to focus on a single biomarker at a single point in development. It is especially important that peripheral biomarkers be evaluated in studies that focus on the same system in the brain, such as serotonin receptor binding studies. Finally, while additional relationships between biomarkers may emerge with further study, the mechanisms underlying these biomarkers and related systems in the brain will be difficult to dissect in humans, given the present limited availability of postmortem brain tissue from children with ASD. Hypotheses generated from human clinical research should therefore be carefully tested using experimental paradigms in animal models, with results then corroborated with human research and eventually translated into testing of novel treatments. The combination of human and rodent studies may allow us to relate peripheral biomarkers to genetic and neural circuit pathology in ASD. While preliminary, our findings point to the promise of connecting biomarker findings across systems and across development, rather than confining our focus to one system at one time point.
Supplementary Material
Table S1
Acknowledgments
This work was supported in part by a Vanderbilt Luton Society Research Award (J.V., E.H.), a National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award (E.H), a National Institutes of Health (NIH) grant K08MH081066 (J.V.), the National Institute of Child Health and Human Development (NICHD) grant P30HD15052 to the Vanderbilt Kennedy Center for Research on Human Development (E.H., J.V.), NIH Autism Center of Excellence grants P50 HD055751 (E.H.C.), and K23MH082121 (S.J.).
We extend our sincere gratitude to all of the families at our research clinics. We gratefully thank Tal Levin- Decannini and Sunday Francis of University of Illinois at Chicago for their assistance with samples, data processing, and their review of this manuscript.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Supplemental material cited in this article is available online.
Disclosure: Dr. Veenstra-VanderWeele has received funding from Seaside Therapeutics, Novartis, and Roche Pharmaceuticals, and has served as a consultant for Novartis. Dr. Cook has served as a consultant for and has received funding from Seaside Therapeutics.
Drs. Hammock, Yan, Morris, Anderson, Carter, and Jacob, and Mr. Kerr report no biomedical financial interests or potential conflicts of interest.
1. Kanner L. Autistic disturbances of affective contact. Nerv. Child. 1943;2:217–250.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed American Psychiatric Association Press, Inc.; Washington, D.C.: 1994.
3. Hus V, Pickles A, Cook EH, Jr., Risi S, Lord C. Using the autism diagnostic interview--revised to increase phenotypic homogeneity in genetic studies of autism. Biol Psychiatry. 2007 Feb 15;61(4):438–448. [PubMed]
4. Tadevosyan-Leyfer O, Dowd M, Mankoski R, et al. A Principal Components Analysis of the Autism Diagnostic Interview-Revised. J Am Acad Child Adolesc Psychiatry. 2003 Jul;42(7):864–872. [PubMed]
5. Liu XQ, Georgiades S, Duku E, et al. Identification of genetic loci underlying the phenotypic constructs of autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2011 Jul;50(7):687–696. e613. [PMC free article] [PubMed]
6. Lam KS, Bodfish JW, Piven J. Evidence for three subtypes of repetitive behavior in autism that differ in familiality and association with other symptoms. J Child Psychol Psychiatry. 2008 Nov;49(11):1193–1200. [PubMed]
7. Snow AV, Lecavalier L, Houts C. The structure of the Autism Diagnostic Interview-Revised: diagnostic and phenotypic implications. J Child Psychol Psychiatry. 2009 Jun;50(6):734–742. [PubMed]
8. Frazier TW, Youngstrom EA, Kubu CS, Sinclair L, Rezai A. Exploratory and confirmatory factor analysis of the autism diagnostic interview-revised. J Autism Dev Disord. 2008 Mar;38(3):474–480. [PubMed]
9. Georgiades S, Szatmari P, Zwaigenbaum L, et al. Structure of the autism symptom phenotype: A proposed multidimensional model. J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):188–196. [PubMed]
10. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry. 2005;162(6):1133–1141. [PubMed]
11. Boyd BA, Baranek GT, Sideris J, et al. Sensory features and repetitive behaviors in children with autism and developmental delays. Autism Res. 2010 Apr;3(2):78–87. [PMC free article] [PubMed]
12. Baranek GT, Boyd BA, Poe MD, David FJ, Watson LR. Hyperresponsive sensory patterns in young children with autism, developmental delay, and typical development. Am J Ment Retard. 2007 Jul;112(4):233–245. [PubMed]
13. Tommerdahl M, Tannan V, Cascio CJ, Baranek GT, Whitsel BL. Vibrotactile adaptation fails to enhance spatial localization in adults with autism. Brain Res. 2007 Jun 18;1154:116–123. [PMC free article] [PubMed]
14. Cascio C, McGlone F, Folger S, et al. Tactile perception in adults with autism: a multidimensional psychophysical study. J Autism Dev Disord. 2008 Jan;38(1):127–137. [PMC free article] [PubMed]
15. Coskun MA, Varghese L, Reddoch S, et al. How somatic cortical maps differ in autistic and typical brains. Neuroreport. 2009 Jan 28;20(2):175–179. [PubMed]
16. Kwakye LD, Foss-Feig JH, Cascio CJ, Stone WL, Wallace MT. Altered auditory and multisensory temporal processing in autism spectrum disorders. Front Integr Neurosci. 2011;4:129. [PMC free article] [PubMed]
17. Volkmar F, Cook E, Jr., Pomeroy J, Realmuto G, Tanguay P. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1611–1616. [PubMed]
18. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008 Aug;47(8):921–929. [PubMed]
19. Canitano R, Luchetti A, Zappella M. Epilepsy, electroencephalographic abnormalities, and regression in children with autism. J Child Neurol. 2005 Jan;20(1):27–31. [PubMed]
20. Goldman SE, Surdyka K, Cuevas R, Adkins K, Wang L, Malow BA. Defining the sleep phenotype in children with autism. Dev Neuropsychol. 2009 Sep;34(5):560–573. [PMC free article] [PubMed]
21. Wang LW, Tancredi DJ, Thomas DW. The Prevalence of Gastrointestinal Problems in Children Across the United States with Autism Spectrum Disorders from Families with Multiple Affected Members. J Dev Behav Pediatr. Jun;32(5):351–60. [PubMed]
22. Ibrahim SH, Voigt RG, Katusic SK, Weaver AL, Barbaresi WJ. Incidence of gastrointestinal symptoms in children with autism: a population-based study. Pediatrics. 2009 Aug;124(2):680–686. [PMC free article] [PubMed]
23. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci. 2006 Oct;7(10):818–827. [PubMed]
24. Gottesman, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003 Apr;160(4):636–645. [PubMed]
25. Weiss LA, Veenstra-Vanderweele J, Newman DL, et al. Genome-wide association study identifies ITGB3 as a QTL for whole blood serotonin. Eur J Hum Genet. 2004 Nov;12(11):949–954. [PubMed]
26. Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: An MRI study. Neurology. 2001 Jul 24;57(2):245–254. [PubMed]
27. Courchesne E, Mouton PR, Calhoun ME, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA. 2011 Nov 9;306(18):2001–2010. [PubMed]
28. Giulivi C, Zhang YF, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. JAMA. 2010 Dec 1;304(21):2389–2396. [PubMed]
29. Hazlett HC, Poe M, Gerig G, et al. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch Gen Psychiatry. 2005 Dec;62(12):1366–1376. [PubMed]
30. Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry. 2005 Jul 1;58(1):1–9. [PubMed]
31. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012 Apr;17(4):389–401. [PMC free article] [PubMed]
32. Schumann CM, Bloss CS, Barnes CC, et al. Longitudinal magnetic resonance imaging study of cortical development through early childhood in autism. J Neurosci. 2010 Mar 24;30(12):4419–4427. [PMC free article] [PubMed]
33. Kuperman S, Beeghly JH, Burns TL, Tsai LY. Serotonin relationships of autistic probands and their first-degree relatives. J Am Acad Child Psychiatry. 1985 Mar;24(2):186–190. [PubMed]
34. Abramson RK, Wright HH, Carpenter R, et al. Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord. 1989 Sep;19(3):397–407. [PubMed]
35. Leventhal BL, Cook EH, Jr., Morford M, Ravitz A, Freedman DX. Relationships of whole blood serotonin and plasma norepinephrine within families. J Autism Dev Disord. 1990 Dec;20(4):499–511. [PubMed]
36. Leboyer M, Philippe A, Bouvard M, et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry. 1999 Jan 15;45(2):158–163. [PubMed]
37. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol. 1999;45(3):287–295. [PubMed]
38. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr. 1961 Mar;58:315–320. [PubMed]
39. Abney M, McPeek MS, Ober C. Broad and narrow heritabilities of quantitative traits in a founder population. Am J Hum Genet. 2001;68(5):1302–1307. [PubMed]
40. Nakamura K, Sekine Y, Ouchi Y, et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry. 2010 Jan;67(1):59–68. [PubMed]
41. Murphy DG, Daly E, Schmitz N, et al. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger’s syndrome: an in vivo SPECT study. Am J Psychiatry. 2006 May;163(5):934–936. [PubMed]
42. Goldberg J, Anderson GM, Zwaigenbaum L, et al. Cortical serotonin type-2 receptor density in parents of children with autism spectrum disorders. J Autism Dev Disord. 2009 Jan;39(1):97–104. [PubMed]
43. Azmitia EC, Singh JS, Whitaker-Azmitia PM. Increased serotonin axons (immunoreactive to 5- HT transporter) in postmortem brains from young autism donors. Neuropharmacology. 2011 Jun;60(7-8):1347–1354. [PubMed]
44. Sacco R, Curatolo P, Manzi B, et al. Principal pathogenetic components and biological endophenotypes in autism spectrum disorders. Autism Res. 2010 Oct;3(5):237–252. [PubMed]
45. Kolevzon A, Newcorn JH, Kryzak L, et al. Relationship between whole blood serotonin and repetitive behaviors in autism. Psychiatry Res. 2010 Feb 28;175(3):274–276. [PMC free article] [PubMed]
46. Kuperman S, Beeghly JHL, Burns TL, Tsai LY. Association of serotonin concentration to behavior and IQ in autistic children. J. Aut. Develop. Disord. 1987;17:133–140. [PubMed]
47. Mulder EJ, Anderson GM, Kema IP, et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry. 2004 Apr;43(4):491–499. [PubMed]
48. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biological Psychiatry. 1998;43(4):270–277. [PubMed]
49. Borden M, Ollendick T. An examination of the validity of social subtypes in autism. J Autism Dev Disord. 1994 Feb;24(1):23–37. [PubMed]
50. Jansen LM, Gispen-de Wied CC, Wiegant VM, Westenberg HG, Lahuis BE, van Engeland H. Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev Disord. 2006 Oct;36(7):891–899. [PubMed]
51. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves “mind-reading” in humans. Biol Psychiatry. 2007 Mar 15;61(6):731–733. [PubMed]
52. Domes G, Heinrichs M, Glascher J, Buchel C, Braus DF, Herpertz SC. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry. 2007 Nov 15;62(10):1187–1190. [PubMed]
53. Ishak WW, Kahloon M, Fakhry H. Oxytocin role in enhancing well-being: a literature review. J Affect Disord. 2011 Apr;130(1-2):1–9. [PubMed]
54. Carter CS, Grippo AJ, Pournajafi-Nazarloo H, Ruscio MG, Porges SW. Oxytocin, vasopressin and sociality. Prog Brain Res. 2008;170:331–336. [PubMed]
55. Carter CS. Developmental consequences of oxytocin. Physiol Behav. 2003;79(3):383–397. [PubMed]
56. Van Wimersma Greidanus TB, Kroodsma JM, Pot ML, Stevens M, Maigret C. Neurohypophyseal hormones and excessive grooming behaviour. Eur J Pharmacol. 1990 Oct 2;187(1):1–8. [PubMed]
57. Winslow JT, Insel TR. Neuroendocrine basis of social recognition. Curr Opin Neurobiol. 2004;14(2):248–253. [PubMed]
58. Sala M, Braida D, Lentini D, et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry. 2011 May 1;69(9):875–882. [PubMed]
59. Takayanagi Y, Yoshida M, Bielsky IF, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16096–16101. Epub 12005 Oct 16025. [PubMed]
60. Wu S, Jia M, Ruan Y, et al. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry. 2005 Jul 1;58(1):74–77. [PubMed]
61. Ylisaukko-oja T, Alarcon M, Cantor RM, et al. Search for autism loci by combined analysis of Autism Genetic Resource Exchange and Finnish families. Ann Neurol. 2006 Jan;59(1):145–155. [PubMed]
62. Campbell DB, Datta D, Jones ST, et al. Association of oxytocin receptor (OXTR) gene variants with multiple phenotype domains of autism spectrum disorder. J Neurodev Disord. 2011 Jun;3(2):101–112. [PMC free article] [PubMed]
63. Gregory SG, Connelly JJ, Towers AJ, et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med. 2009;7:62. [PMC free article] [PubMed]
64. Lerer E, Levi S, Salomon S, Darvasi A, Yirmiya N, Ebstein RP. Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry. 2008 Oct;13(10):980–988. [PubMed]
65. Jacob S, Brune CW, Carter CS, Leventhal BL, Lord C, Cook EH., Jr. Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci Lett. 2007 Apr 24;417(1):6–9. [PMC free article] [PubMed]
66. Liu X, Kawamura Y, Shimada T, et al. Association of the oxytocin receptor (OXTR) gene polymorphisms with autism spectrum disorder (ASD) in the Japanese population. Journal of Human Genetics. 2010;55(3):137–141. [PubMed]
67. Wermter AK, Kamp-Becker I, Hesse P, Schulte-Korne G, Strauch K, Remschmidt H. Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR) in the etiology of autistic disorders on high-functioning level. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):629–639. [PubMed]
68. Yrigollen CM, Han SS, Kochetkova A, et al. Genes controlling affiliative behavior as candidate genes for autism. Biol Psychiatry. 2008 May 15;63(10):911–916. [PMC free article] [PubMed]
69. Tansey KE, Brookes KJ, Hill MJ, et al. Oxytocin receptor (OXTR) does not play a major role in the aetiology of autism: genetic and molecular studies. Neurosci Lett. 2010 May 3;474(3):163–167. [PubMed]
70. Kelemenova S, Schmidtova E, Ficek A, Celec P, Kubranska A, Ostatnikova D. Polymorphisms of candidate genes in Slovak autistic patients. Psychiatr Genet. 2010 Aug;20(4):137–139. [PubMed]
71. Higashida H, Yokoyama S, Munesue T, Kikuchi M, Minabe Y, Lopatina O. CD38 gene knockout juvenile mice: a model of oxytocin signal defects in autism. Biol Pharm Bull. 2011;34(9):1369–1372. [PubMed]
72. Jin D, Liu HX, Hirai H, et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature. 2007 Mar 1;446(7131):41–45. [PubMed]
73. Lerer E, Levi S, Israel S, et al. Low CD38 expression in lymphoblastoid cells and haplotypes are both associated with autism in a family-based study. Autism Res. 2010 Dec;3(6):293–302. [PubMed]
74. Munesue T, Yokoyama S, Nakamura K, et al. Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci Res. 2010 Jun;67(2):181–191. [PubMed]
75. Hollander E, Novotny S, Hanratty M, et al. Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger’s Disorders. Neuropsychopharmacology. 2003 Jan;28(1):193–198. [PubMed]
76. Hollander E, King A, Delaney K, Smith CJ, Silverman JM. Obsessive-compulsive behaviors in parents of multiplex autism families. Psychiatry Res. 2003 Jan 25;117(1):11–16. [PubMed]
77. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007 Feb 15;61(4):498–503. [PubMed]
78. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010 Apr 1;67(7):692–694. [PubMed]
79. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4389–4394. [PubMed]
80. McNamara IM, Borella AW, Bialowas LA, Whitaker-Azmitia PM. Further studies in the developmental hyperserotonemia model (DHS) of autism: social, behavioral and peptide changes. Brain Res. 2008 Jan 16;1189:203–214. [PubMed]
81. Martin MM, Liu Y, Wang Z. Developmental exposure to a serotonin agonist produces subsequent behavioral and neurochemical changes in the adult male prairie vole. Physiol Behav. 2011 Sep 17;105(2):529–535. [PMC free article] [PubMed]
82. Eaton JL, Roache L, Nguyen KN, et al. Organizational effects of oxytocin on serotonin innervation. Dev Psychobiol. 2012 Jan;54(1):92–97. [PubMed]
83. Kent DL, Sladek JR., Jr. Histochemical, pharmacological and microspectrofluorometric analysis of new sites of serotonin localization in the rat hypothalamus. J Comp Neurol. 1978 Jul 15;180(2):221–236. [PubMed]
84. Emiliano AB, Cruz T, Pannoni V, Fudge JL. The interface of oxytocin-labeled cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for SSRIs therapeutic effects? Neuropsychopharmacology. 2007 May;32(5):977–988. [PubMed]
85. Jorgensen H, Riis M, Knigge U, Kjaer A, Warberg J. Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol. 2003 Mar;15(3):242–249. [PubMed]
86. Saydoff JA, Rittenhouse PA, van de Kar LD, Brownfield MS. Enhanced serotonergic transmission stimulates oxytocin secretion in conscious male rats. J Pharmacol Exp Ther. 1991 Apr;257(1):95–99. [PubMed]
87. Bagdy G, Kalogeras KT. Stimulation of 5-HT1A and 5-HT2/5-HT1C receptors induce oxytocin release in the male rat. Brain Res. 1993 May 21;611(2):330–332. [PubMed]
88. Bagdy G, Kalogeras KT, Szemeredi K. Effect of 5-HT1C and 5-HT2 receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations. Eur J Pharmacol. 1992 Dec 8;229(1):9–14. [PubMed]
89. Yoshida M, Takayanagi Y, Inoue K, et al. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci. 2009 Feb 18;29(7):2259–2271. [PubMed]
90. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994 Oct;24(5):659–685. [PubMed]
91. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000 Jun;30(3):205–223. [PubMed]
92. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry. 1998 Feb 15;43(4):270–277. [PubMed]
93. Anderson GM, Stevenson JM, Cohen DJ. Steady-state model for plasma free and platelet serotonin in man. Life Sci. 1987 Oct 12;41(15):1777–1785. [PubMed]
94. Anderson GM, Young JG, Cohen DJ, Schlicht KR, Patel N. Liquid-chromatographic determination of serotonin and tryptophan in whole blood and plasma. Clin Chem. 1981 May;27(5):775–776. [PubMed]
95. Bazalakova MH, Wright J, Schneble EJ, et al. Deficits in acetylcholine homeostasis, receptors and behaviors in choline transporter heterozygous mice. Genes Brain Behav. 2007 Jul;6(5):411–424. [PubMed]
96. Cook EH, Jr., Leventhal BL, Freedman DX. Free serotonin in plasma: autistic children and their first-degree relatives. Biol Psychiatry. 1988 Aug;24(4):488–491. [PubMed]
97. Anderson GM, Hertzig ME, McBride PA. Brief Report: Platelet-Poor Plasma Serotonin in Autism. J Autism Dev Disord. [published online ahead of print Oct 2011] DOI: 10.1007/s10803-011-1371-1. [PubMed]
98. Spivak B, Golubchik P, Mozes T, et al. Low platelet-poor plasma levels of serotonin in adult autistic patients. Neuropsychobiology. 2004;50(2):157–160. [PubMed]
99. Cross S, Kim SJ, Weiss LA, et al. Molecular genetics of the platelet serotonin system in first- degree relatives of patients with autism. Neuropsychopharmacology. 2008 Jan;33(2):353–360. [PMC free article] [PubMed]
100. McBride PA, Anderson GM, Hertzig ME, et al. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry. 1998 Jul;37(7):767–776. [PubMed]
101. Ritvo E, Yuwiler A, Geller E, Plotkin S, Mason A, Saeger K. Maturational changes in blood serotonin levels and platelet counts. Biochem Med. 1971;5(1):90–96. [PubMed]
102. Welch MG, Tamir H, Gross KJ, Chen J, Anwar M, Gershon MD. Expression and developmental regulation of oxytocin (OT) and oxytocin receptors (OTR) in the enteric nervous system (ENS) and intestinal epithelium. J Comp Neurol. 2009 Jan 10;512(2):256–270. [PMC free article] [PubMed]